Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413286 | 0.89 | SMN1; SMN2 (0.81) | SMN1; SMN2POLBMAPTHTR2BHSD17B10 | |
| SCHEMBL1299510 | 0.83 | HTR2B (1.00) | SMN1; SMN2HTR2B | |
| SCHEMBL20456432 | 0.77 | KMT2A (0.74) | SMN1; SMN2MAPTHTR2B | |
| SCHEMBL20463352 | 0.77 | HTR2B (0.62) | SMN1; SMN2POLBMAPTHTR2BTRPV1 | |
| SCHEMBL14413511 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBMAPTHTR2BHSD17B10 | |
| SCHEMBL13873072 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2POLBMAPTHTR2BHSD17B10 | |
| SCHEMBL13873292 | 0.76 | EPHX2 (0.69) | POLBEPHX2CYP2C9CYP2C19CCR2 | |
| SCHEMBL20463333 | 0.75 | HTR2B (0.60) | SMN1; SMN2POLBMAPTHTR2BTRPV1 | |
| SCHEMBL2069264 | 0.75 | EPHX2 (0.52) | HTR2BEPHX2 | |
| Hydrochloric Acid SCHEMBL2067257 | 0.75 | EPHX2 (0.52) | HTR2BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | SMN1; SMN2 4277/4885POLB 1775/4885MAPT 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.